Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

Blood

Volumn 104, Issue 9, 2004, Pages 2667-2674

  Lenz, Georg ^b   Dreyling, Martin ^b   Schiegnitz, Eva ^b   Forstpointner, Roswitha ^b   Wandt, Hannes ^b   Freund, Mathias ^b   Hess, Georg ^b   Truemper, Lorenz ^b   Diehl, Volker ^b   Kropff, Martin ^b   Kneba, Michael ^b   Schmitz, Norbert ^b   Metzner, Bernd ^b   Pfirrmann, Markus ^b   Unterhalt, Michael ^b   Hiddemann, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 7244258905     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-0982     Document Type: Article

References (38)

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20:75-88.
2. Mounier N, Socie G, Gisselbrecht C. High-dose therapy for indolent lymphoma. Crit Rev Oncol Hernatol. 2002;41:225-239.
3. Hiddemann W. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol. 2003;14:1163-1164.
4. Rohatiner AZ, Gregory WM, Peterson B, et al. A meta-analysis of randomised studies evaluating the role of interferon alpha as treatment for follicular lymphoma (FL) [abstract]. Proceedings ASCO. 2002;21:264.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
6. Ghielmini M, Schmitz SF, Burki K, et al. The effect of Rituximab on patients with follicular and mantle-cell lymphoma: Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2000;11:123-126.
7. Maloney DG. Rituximab for follicular lymphoma. Curr Hematol Rep. 2003;2:13-22.
8. Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002;29:36-40.
9. Zinzani PL. A multicenter randomized trial of fludarabine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma (FL) [abstract]. Blood. 2002;100:93.
10. Jaeger G, Neumeister P, Brezinschek R, et al. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haematol. 2002;69:21-26.
11. Hiddemann W, Dreyling MH, Forstpointner R, et al. Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first-line therapy of follicular lymphoma-results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) [abstract]. Blood. 2003;102:104a.
12. Apostolidis J, Foran JM, Johnson PW, et al. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol. 1999;17:216-221.
13. Voso MT, Martin S, Hohaus S, et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant. 2000;25:957-964.
14. Berglund A, Enblad G, Carlson K, Glimelius B, Hagberg H. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol. 2000;65:17-22.
15. Freedman AS, Neuberg D, Mauch P, et at. Longterm follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325-3333.
16. Weaver CH, Schwartzberg L, Rhinehart S, et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998;21:383-389.
17. Jaffe ES, Harris NL, Stein H, Vardiman J. World Health Organisation Classification of Tumours: Tumours of the Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
18. Hiddemann W, Griesinger F, Unterhalt M. Interferon alfa for the treatment of follicular lymphomas. Cancer J Sci Am. 1998;(suppl 2):S13-S18.
19. World Health Organization. A Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO Publication 38; 1979.
20. A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
21. Whitehead J. The Design and Analysis of Sequential Clinical Trials. 2nd ed. Chichester, United Kingdom: Horwood; 1992.
22. Pettengell R. Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. Bone Marrow Transplant. 2002;(suppl 1):S1-S4.
23. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325:1525-1533.
24. Freedman AS, Gribben JG, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996;88:2780-2786.
25. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
26. Seyfarth B, Kuse R, Sonnen R, Glass B, Schmitz N, Dreger P. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? Ann Hematol. 2001;80:398-405.
27. Hess G, Flohr T, Huber C, Kolbe K, Derigs HG, Fischer T. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;31:775-782.
28. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918-3927.
29. Sebban C, Coiffier B, Belanger C, et al. A randomized trial in follicular lymphoma comparing a standard chemotherapy regimen with 4 courses of CHOP followed by autologous stem cell transplantation with TBI: the GELF94 trial from GELA [abstract]. Hematol J. 2003;4:150.
30. Ladetto M, Corradini P, Vallet S, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood. 2002;100:1559-1565.
31. Homing SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001;97:404-409.
32. Deconinck E, Foussard C, Bertrand P-P, et al. Value of autologous stem cell transplantation in first-line therapy of follicular lymphoma with high tumor burden: final results of the randomized GOELAMS 064 Trial [abstract]. Blood. 2003;102:246.
33. Lenz G, Unterhalt M, Haferlach T, Hiddemann W, Dreyling MH. Significant increase of secondary myelodysplasia and acute myeloid leukemia after myeloablative radiochemotherapy followed by autologous stem cell transplantation in indolent lymphoma patients: results of a prospective randomized study for the GLSG [abstract]. Blood. 2003;102:986.
34. Van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521-3529.
35. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96:864-869.
36. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102:749-755.
37. Tothova E, Kafkova A, Guman T, Stecova N, Fricova M. Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas. Neoplasma. 2003;50:22-25.
38. Hess G, Flohr T, Derigs HG. Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL. Ann Hematol. 2002;81(suppl 2):S54-S55.